Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is GenVec, Inc. (GNVC) A Good Stock To Buy?

Page 1 of 2

Out of thousands of stocks that are currently traded on the market, it is difficult to determine those that can really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback the hedge funds employing these talents and can benefit from their vast resources and knowledge in that way. We analyze quarterly 13F filings of over 700 hedge funds and, by looking at the smart money sentiment that surrounds a stock, we can determine whether it has potential to beat the market over the long-term. Therefore, let’s take a closer look at what smart money thinks about GenVec, Inc. (NASDAQ:GNVC).

Is GenVec, Inc. (NASDAQ:GNVC) the right investment to pursue these days? The smart money is becoming less confident. The number of long hedge fund positions dropped by 1 in recent months. What is even more surprising is the fact that the shares of GenVec, Inc. (NASDAQ:GNVC) were up 13.24% during the third quarter. We decided to find out more about the hedge fund sentiment by cover hedge funds that held positions in the company, at the end of the previous quarter.

In order to understand overall hedge fund behavior, we will also compare GenVec, Inc. (NASDAQ:GNVC) to other stocks, including Novacopper Inc (NYSEMKT:NCQ), LiqTech International Inc (NYSEMKT:LIQT), and Nuverra Environmental Solutions Inc (NYSE:NES) to get a better sense of its popularity.

Follow Genvec Inc (NASDAQ:GNVC)
Trade (NASDAQ:GNVC) Now!

To most market participants, hedge funds are seen as worthless, old financial vehicles of yesteryear. While there are more than 8000 funds in operation at the moment, Our experts choose to focus on the bigwigs of this club, around 700 funds. These hedge fund managers shepherd most of all hedge funds’ total asset base, and by watching their top investments, Insider Monkey has figured out numerous investment strategies that have historically exceeded the broader indices. Insider Monkey’s small-cap hedge fund strategy outstripped the S&P 500 index by 12 percentage points per year for a decade in their back tests.

With all of this in mind, we’re going to take a look at the fresh action encompassing GenVec, Inc. (NASDAQ:GNVC).

Hedge fund activity in GenVec, Inc. (NASDAQ:GNVC)

Heading into Q4, a total of 5 of the hedge funds tracked by Insider Monkey held long positions in this stock, a decrease of 17% from the previous quarter. With hedge funds’ sentiment swirling, there exists a select group of key hedge fund managers who were upping their holdings significantly (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, EcoR1 Capital, managed by Oleg Nodelman, holds the biggest position in GenVec, Inc. (NASDAQ:GNVC). EcoR1 Capital has a $4.6 million position in the stock, comprising 2.1% of its 13F portfolio. Coming in second is Cormorant Asset Management, led by Bihua Chen, holding a $2.7 million position; the fund has 0.4% of its 13F portfolio invested in the stock. Some other members of the smart money with similar optimism contain Joseph Edelman’s Perceptive Advisors, Nathan Fischel’s DAFNA Capital Management, and Renaissance Technologies.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!